

IMUNON posts rapid patient enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting completion by Q2 2029.
You can purchase shares of Imunon (NASDAQ:IMNN) through any online brokerage.
Other companies in Imunon’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Imunon has a consensus price target of $190.29.
The stock price for Imunon (NASDAQ: IMNN) is $0.9555 last updated October 30, 2026 at 6:38 PM EDT.
There are no upcoming dividends for Imunon.
Imunon does not have any upcoming earnings scheduled.
There is no upcoming split for Imunon.
Imunon is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a...